A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy

Status Completed

Clinical Trial Summary

The goal of this study is to identify changes in cells that are related to the treatment with Cat-PAD (ToleroMune Cat).

Clinical Trial Description

Cat-PAD is an experimental cat allergy vaccine and has been studied to determine if it can reduce symptom scores of participants exposed to cat allergen. To study how the vaccine causes changes in the immune system, the researchers plan to evaluate changes in the blood (genes and proteins) and urine in response to the Cat-PAD vaccine. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02311413
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase	Phase 2
Start date	March 9, 2015
Completion date	July 18, 2018

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02959073` - Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients	N/A
Completed	`NCT00987909` - Exposure Chamber Trial With Cat Immunotherapy	Phase 2
Completed	`NCT01383590` - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis	Phase 1
Completed	`NCT01383603` - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis	Phase 1
Completed	`NCT01003301` - The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge	Phase 2
Completed	`NCT02237196` - Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy	Phase 1/Phase 2
Completed	`NCT02399579` - Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients	N/A
Terminated	`NCT01292070` - Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy	Phase 0
Completed	`NCT00867906` - Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma	Phase 2
Completed	`NCT04435678` - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens	N/A
Completed	`NCT01033344` - Cat-PAD Exposure Chamber Study	Phase 2
Completed	`NCT00685711` - Safety of Cat-PAD in Cat Allergic Subjects	Phase 1/Phase 2
Completed	`NCT02040844` - Phase III Cat-PAD Follow-on Study	Phase 3
Completed	`NCT01604018` - An Optional Two Year Follow Up Study to Study CP005A	N/A
Completed	`NCT01272323` - Cat-PAD Follow on Study	N/A
Completed	`NCT03838731` - Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge	Phase 2
Completed	`NCT00729508` - Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects	Phase 2
Recruiting	`NCT05331170` - Viral Mucosal Reprogramming	Phase 2